BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okuyama M, Nakahara K, Iwakura N, Hasegawa T, Oyama M, Inoue A, Ishizu H, Satoh H, Fujiwara Y. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Digestion 2017;95:281-7. [PMID: 28501868 DOI: 10.1159/000475658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Lee M, Kim J, Kim P, Lee I, Mswahili ME, Jeong Y, Choi GJ. Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery. Pharmaceutics 2022;14:429. [DOI: 10.3390/pharmaceutics14020429] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hwang S, Ko JW, Lee H, Kim S, Kim B, Song GS, Kim J. Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. Front Pharmacol 2021;12:754849. [PMID: 34867368 DOI: 10.3389/fphar.2021.754849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, Marchi S, de Bortoli N, Zerbib F, Savarino E, Bellini M. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne) 2021;8:765061. [PMID: 34790683 DOI: 10.3389/fmed.2021.765061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
4 Shinozaki S, Osawa H, Hayashi Y, Miura Y, Lefor AK, Yamamoto H. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep 2021;14:32. [PMID: 33585034 DOI: 10.3892/br.2021.1408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Shimamura Y, Inoue H. Anti-reflux Mucosectomy and Anti-reflux Mucosal Ablation. Innovations in Gastrointestinal Endoscopy 2021. [DOI: 10.1007/978-981-15-9247-8_7] [Reference Citation Analysis]
6 Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. The Lancet 2020;396:1689-702. [DOI: 10.1016/s0140-6736(20)30469-4] [Cited by in Crossref: 106] [Cited by in F6Publishing: 118] [Article Influence: 53.0] [Reference Citation Analysis]
7 Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021;22:219-27. [PMID: 32893683 DOI: 10.1080/14656566.2020.1817385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
8 Shimamura Y, Inoue H. Anti‐reflux mucosectomy: Can we do better? Digestive Endoscopy 2020;32:736-8. [DOI: 10.1111/den.13632] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Gotoh Y, Ishibashi E, Honda S, Nakaya T, Noguchi C, Kagawa K, Murakami K. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine (Baltimore) 2020;99:e19520. [PMID: 32176102 DOI: 10.1097/MD.0000000000019520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Miyazaki H, Igarashi A, Takeuchi T, Teng L, Uda A, Deguchi H, Higuchi K, Tango T. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. J Gastroenterol Hepatol 2019;34:1316-28. [PMID: 30883868 DOI: 10.1111/jgh.14664] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
11 Hoshikawa Y, Kawami N, Hoshino S, Tanabe T, Umezawa M, Kaise M, Iwakiri K. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus 2019;16:201-6. [PMID: 30600486 DOI: 10.1007/s10388-018-00654-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
12 Miyamoto S, Tsuda M, Kato M, Mabe K, Muto S, Ono S, Shimizu Y, Sakamoto N. Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test. J Clin Biochem Nutr 2019;64:174-9. [DOI: 10.3164/jcbn.18-75] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis. Medicine (Baltimore) 2018;97:e12574. [PMID: 30278564 DOI: 10.1097/MD.0000000000012574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Roman S, Mion F. Refractory GERD, beyond proton pump inhibitors. Curr Opin Pharmacol 2018;43:99-103. [PMID: 30240968 DOI: 10.1016/j.coph.2018.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
15 Umezawa M, Kawami N, Hoshino S, Hoshikawa Y, Koizumi E, Takenouchi N, Hanada Y, Kaise M, Iwakiri K. Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis. Digestion 2018;97:309-15. [PMID: 29514137 DOI: 10.1159/000485795] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
16 Suzuki H. New Medical Approach to Functional Dyspepsia, from Core Symposium 3, Japan Gastroenterological Association 2015-2017. Digestion 2018;97:6-12. [PMID: 29393229 DOI: 10.1159/000484029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kojima Y, Takeuchi T, Sanomura M, Higashino K, Kojima K, Fukumoto K, Takata K, Sakamoto H, Sakaguchi M, Tominaga K, Higuchi K. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study. Digestion 2018;97:70-5. [PMID: 29393198 DOI: 10.1159/000484217] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
18 Mizuno H, Yamada K, Minouchi K, Kamiyamamoto S, Hinoue Y. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Biomed Rep 2018;8:148-55. [PMID: 29435273 DOI: 10.3892/br.2017.1035] [Reference Citation Analysis]
19 Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018;97:212-8. [PMID: 29393194 DOI: 10.1159/000485097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
20 Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776. [PMID: 29383028 DOI: 10.1177/1756283x17745776] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
21 Shiotani A, Katsumata R, Gouda K, Fukushima S, Nakato R, Murao T, Ishii M, Fujita M, Matsumoto H, Sakakibara T. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018;97:154-62. [DOI: 10.1159/000484688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
22 Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi T, Fujita M, Okada A. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors. Digestion 2017;96:52-9. [PMID: 28662503 DOI: 10.1159/000478255] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]